Liftstream is an executive search recruitment company in the life sciences sector
M&A Continues to Dominate the Rare Diseases Landscape
Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be in the M&A cross-hairs of both pharmaceutical and big-biotech companies.
Posted in Orphan Drugs and Rare Diseases
Tagged AbbVie, Actelion, Alexion, bioValley, Boston, Boston Biotech, Flemming Ornskov, M&A, NPS Pharmaceuticals, Orphan Drug, Pfizer, Rare Disease, Shire, SOBI, Swiss, Synageva
Leave a comment
AM-Pharma raises 12.2m Euros
Authored by James Sheppard
UK Government names biotech veteran Minister for Life Sciences
Authored by James Sheppard
Posted in Executive Appointments, M&A Finance and Funding, Pharmaceutical business
Tagged AbbVie, AstraZeneca, Britain, George Freeman, London Biotech, medical research, Merlin Biosciences, Minister for Life Sciences, NHS, One Nucleus, Oxford Biotech, Pfizer, Shire, Stevenage Biotech, Takeda, UK, UK government
Leave a comment
Mr Richard Gonzalez – AbbVie – Executive Leadership Series
Posted in Pharmaceutical business
Tagged Abbot Laboratories, AbbVie, Ablynx, Galapagos, Hep C, Humira, Richard Gonzalez, seattle genetics, Veliparib
Leave a comment
Ablynx and AbbVie sign inflammatory disease agreement
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged AbbVie, Ablynx, ALX-0061, Belgium, clincal trials, Ed Moses, Flanders Biotech, Humira, Luxembourg, Merck Serono, methotrexate, monoclonal antibody, Netherlands, Phase II, rheumatoid arthritis, systemic lupus erythematosus
Leave a comment
13 Life Science Leaders to watch in 2013
Authored by Liftstream
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Abbott, AbbVie, Amgen, Angus Russell, AstraZeneca, Bluebird bio, Cancer Vaccine, CEO, Cystic Fibrosis, Dalvir Gill, David Mott, Director General EFPIA, EFPIA, EMEA, Erbitux, FDA, Flemming Ornskov, Foundation Medicine, FoundationOne, Gattex, Gene therapy, Gilead Sciences, Glybera, HCV, Hepatitis, Humira, INSPIRE, Jeff Leiden, Jeremy Levin, John Martin, Kalydeco, Karl-Ludwig Kley, Lotus Tissue Repair, Merck KGaA, Michael Pellini, Natpara, New Enterprise Associates, NP Pharmaceuticals, oncology, Orphan drugs, Pascal Soriot, rare diseases, Richard Bergstrom, Richard Gonzalez, Shire, Shire Speciality pharma, Sofosbuvir, Stimuvax, Takeda, Teva, TransCelerate, Ultragenyx, uniQure, Vertex Pharmaceuticals, Vyvanse
Leave a comment